ClinicaliQ Trial Snapshot
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes — Recruiting • Phase III • Diabetes / Metabolic • NCT07284979.
- What is being tested: Ribupatide (KAI-9531), a novel once-weekly subcutaneous injection, is being evaluated for weight reduction in people with obesity without diabetes, compared directly against semaglutide and placebo in a head-to-head efficacy and safety trial.
- Patient eligibility overview: The study recruits participants with obesity (likely BMI ≥30 kg/m²) who do not have diabetes, making this a trial specifically examining efficacy in non-diabetic populations where weight management is the primary therapeutic goal.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Eligibility Snapshot
- Key Inclusion Criteria: * BMI ≥35 kilograms per square meter (kg/m^2). * History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months. Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.